STOK Strangle Strategy
STOK (Stoke Therapeutics, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression. Stoke's most advanced candidate, STK-001, is currently progressing through Phase I/IIa clinical trials for Dravet syndrome, a severe and debilitating genetic epilepsy. Additionally, STK-002 is in the preclinical development stage for treating autosomal dominant optic atrophy. The company has also established a licensing and collaborative agreement with Acadia Pharmaceuticals Inc. to identify, develop, and market new RNA-based medicines for critical and rare genetic neurodevelopmental conditions impacting the central nervous system.
STOK (Stoke Therapeutics, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $1.99B, a beta of 1.19 versus the broader market, a 52-week range of 11.19-40.22, average daily share volume of 642K, a public-listing history dating back to 2019, approximately 128 full-time employees. These structural characteristics shape how STOK stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.19 places STOK roughly in line with broader market moves, so the strategy payoff and realized volatility track the index-equivalent baseline.
What is a strangle on STOK?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current STOK snapshot
As of June 29, 2026, spot at $32.34, ATM IV 69.80%, IV rank 11.57%, expected move 20.01%. The strangle on STOK below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 18-day expiry.
Why this strangle structure on STOK specifically: STOK IV at 69.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a STOK strangle, with a market-implied 1-standard-deviation move of approximately 20.01% (roughly $6.47 on the underlying). The 18-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated STOK expiries trade a higher absolute premium for lower per-day decay. Position sizing on STOK should anchor to the underlying notional of $32.34 per share and to the trader's directional view on STOK stock.
STOK strangle setup
The STOK strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With STOK near $32.34, the first option leg uses a $33.96 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed STOK chain at a 18-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 STOK shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $33.96 | N/A |
| Buy 1 | Put | $30.72 | N/A |
STOK strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
STOK strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on STOK. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on STOK
Strangles on STOK are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the STOK chain.
STOK thesis for this strangle
The market-implied 1-standard-deviation range for STOK extends from approximately $25.87 on the downside to $38.81 on the upside. A STOK long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current STOK IV rank near 11.57% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on STOK at 69.80%. As a Healthcare name, STOK options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to STOK-specific events.
STOK strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. STOK positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move STOK alongside the broader basket even when STOK-specific fundamentals are unchanged. Always rebuild the position from current STOK chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on STOK?
- A strangle on STOK is the strangle strategy applied to STOK (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With STOK stock trading near $32.34, the strikes shown on this page are snapped to the nearest listed STOK chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are STOK strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the STOK strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 69.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a STOK strangle?
- The breakeven for the STOK strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current STOK market-implied 1-standard-deviation expected move is approximately 20.01%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on STOK?
- Strangles on STOK are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the STOK chain.
- How does current STOK implied volatility affect this strangle?
- STOK ATM IV is at 69.80% with IV rank near 11.57%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.